Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Efficacy and Tolerability of Erenumab for Prevention of Episodic Migraine in India.

< BACK TO ARCHIVE


2022 May-Jun


Ann Indian Acad Neurol


http://www.ncbi.nlm.nih.gov/pubmed/35936611?dopt=Abstract


25


3

Efficacy and Tolerability of Erenumab for Prevention of Episodic Migraine in India.

Authors

Efficacy and Tolerability of Erenumab for Prevention of Episodic Migraine in India.
Chowdhury D, Chaudhuri JR, Ghosh P, Kulkarni R, Singh S, Thakur S, Thorat AV
Ann Indian Acad Neurol. 2022 May-Jun; 25(3):433-440.
PMID: 35936611.

Abstract

EMPOwER, a 12-week, double-blind (DB), randomized, placebo-controlled study evaluated the efficacy and safety of erenumab in adult patients with episodic migraine (EM) from Asia, the Middle East, and Latin America. This study analyzes the Indian experience for the use of erunumab for prevention of episodic migraine.
Read This Paper